ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: TH-PO030

Cyclophilin D Interacts with PPARα to Regulate Fatty Acid Oxidation in Cisplatin AKI

Session Information

Category: Acute Kidney Injury

  • 103 AKI: Mechanisms

Authors

  • Jang, Hee-Seong, University of Nebraska Medical Center, Omaha, Nebraska, United States
  • Noh, Mira, University of Nebraska Medical Center, Omaha, Nebraska, United States
  • Padanilam, Babu J., University of Nebraska Medical Center, Omaha, Nebraska, United States
Background

Regardless of the etiology, acute kidney injury (AKI) involves aspects of mitochondrial dysfunction and ATP depletion. Fatty acid oxidation (FAO) is the preferred energy source of the kidney and is inhibited during AKI. A pivotal role for the mitochondrial matrix protein, cyclophilin D (CypD) in regulating overall cell metabolism is being unraveled. We hypothesize that mitochondrial interaction of proximal tubule CypD and PPARα modulate FAO in cisplatin-induced AKI (cisplatin AKI).

Methods

Using genetic and pharmacological intervention and protein-protein interaction studies, we investigated whether proximal tubule CypD modulates FAO in cisplatin AKI through mitochondrial CypD-PPARα binding and its sequestration.

Results

Cisplatin injury resulted in histological and functional damage in the kidney with downregulation of FAO genes and increase of intrarenal lipid accumulation. However, proximal tubule (PT)-specific deletion of CypD protected cisplatin-induced renal damage by inhibiting impairment of FAO and intrarenal lipid accumulation. Immunoprecipitation and BioID methods demonstrated mitochondrial translocation of PPARα and its binding to CypD and sequestration. This led to inhibition of nuclear translocation of PPARα and transcription of PPARα-regulated FAO genes during cisplatin AKI. Genetic or pharmacological inhibition of CypD suppressed mitochondrial CypD-PPARα binding in cisplatin AKI, preventing the impairment of FAO and intracellular lipid accumulation.

Conclusion

These results uncover a novel mechanism by which mitochondrial interaction between CypD and PPARα impairs FAO in cisplatin AKI. Targeting their interaction may be a potential therapeutic strategy to prevent energy depletion and cell death in AKI.

Funding

  • NIDDK Support